2-溴-6-氟甲苯 | 1422-54-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟甲苯系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-6-氟甲苯
• 中文别名: 1-溴-3-氟-2-甲苯；6-溴-2-氟甲苯；2-氟-6-溴甲苯
• 英文名称: 1-bromo-3-fluoro-2-methylbenzene
• 英文别名: 2-bromo-6-fluorotoluene
• CAS: 1422-54-4
• 化学式: C₇H₆BrF
• mdl: MFCD00051438
• 分子量: 189.027
• InChiKey: DJGXPFQIMLEVPA-UHFFFAOYSA-N

物化性质

• 沸点：
  75-76°C 10mm
• 密度：
  1.53
• 闪点：
  76°C
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险反应。请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2903999090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H227,H315,H319,H335
• 储存条件：
  请将贮藏器密封，并将其存放在阴凉、干燥处。确保工作环境有良好的通风或排气设施。

SDS

2-Bromo-6-fluorotoluene Revision number: 1
SAFETY DATA SHEET

---

Section 1. BASE INFORMATION
Product name: 2-Bromo-6-fluorotoluene

Revision number: 1

---

Section 2. HAZARDS IDENTIFICATION
Classification of the GHS
PHYSICAL HAZARDS
Flammable liquids Category 4
HEALTH HAZARDS
Skin corrosion/irritation Category 2
Category 2A
Serious eye damage/eye irritation
ENVIRONMENTAL HAZARDS Not classified
GHS label elements
Pictograms or hazard symbols
Signal word Warning
Hazard statement Combustible liquid
Causes skin irritation
Causes serious eye irritation
Precautionary statements
[Prevention] Keep away from flames and hot surfaces.
Wash hands thoroughly after handling.
Wear protective gloves and eye/face protection.
IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses,
[Response]
if present and easy to do. Continue rinsing.
If eye irritation persists: Get medical advice/attention.
IF ON SKIN: Gently wash with plenty of soap and water.
If skin irritation occurs: Get medical advice/attention.
Take off contaminated clothing and wash before reuse.
Store in a well-ventilated place. Keep cool.
[Storage]
[Disposal] Dispose of contents/container through a waste management company authorized by
the local government

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Component(s): 2-Bromo-6-fluorotoluene
>98.0%(GC)
Percent:
CAS Number: 1422-54-4
1-Bromo-3-fluoro-2-methylbenzene
Synonyms:
Chemical Formula: C7H6BrF
2-Bromo-6-fluorotoluene

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
Skin contact: Remove/Take off immediately all contaminated clothing. Gently wash with plenty of
soap and water. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
Protection of first-aiders: A rescuer should wear personal protective equipment, such as rubber gloves and air-
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Extinguishing media not to Solid streams of water
be used:
Specific hazards: Take care as it may decompose upon combustion or in high temperatures to
generate poisonous fume.
Specific methods: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
When extinguishing fire, be sure to wear personal protective equipment.
Special protective
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Use personal protective equipment. Keep people away from and upwind of spill/leak.
Personal precautions,
protective equipment and Ensure adequate ventilation. Entry to non-involved personnel should be controlled
emergency procedures: around the leakage area by roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Absorb spilled material in a suitable absorbent (e.g. rag, dry sand, earth, saw-dust).
containment and cleaning In case of large amount of spillage, contain a spill by bunding. Adhered or collected
up: material should be promptly disposed of, in accordance with appropriate laws and
regulations.
Prevention of secondary Remove all sources of ignition. Fire-extinguishing devices should be prepared in
hazards: case of a fire. Use spark-proof tools and explosion-proof equipment.

---

Section 7. HANDLING AND STORAGE
Handling
Technical measures: Handling is performed in a well ventilated place. Wear suitable protective equipment.
Prevent generation of vapor or mist. Keep away from flames and hot surfaces. Take
measures to prevent the build up of electrostatic charge. Use explosion-proof
equipment. Wash hands and face thoroughly after handling.
Use a closed system, ventilation.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Storage
Storage conditions: Keep container tightly closed. Store in a cool, dark and well-ventilated place.
Store away from incompatible materials such as oxidizing agents.
Packaging material: Law is followed.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Install a closed system or local exhaust as possible so that workers should not be
Engineering controls:
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Vapor respirator. Follow local and national regulations.
2-Bromo-6-fluorotoluene

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Liquid
clear
Form:
Color: Colorless - Very pale yellow
Odor: No data available
pH: No data available
Melting point/freezing point:No data available
Boiling Point/Range: 180 °C
Flash Point: 76°C
Explosive limits
No data available
Lower:
Upper: No data available
Density: 1.53
Solubility: No data available

---

Section 10. STABILITY AND REACTIVITY
Stability: Stable under proper conditions.
Reactivity: No special reactivity has been reported.
Incompartible materials: oxidizing agents
Hazardous Decomposition Carbon monoxide, Carbon dioxide, Hydrogen fluoride, Hydrogen bromide
Products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: No data available
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
No data available
IARC =
NTP = No data available
No data available
Reproductive toxicity:

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: No data available
Crustacea: No data available
Algae: No data available
Persistence / degradability: No data available
Bioaccumulative No data available
potential(BCF):
Mobillity in soil
log Pow: No data available
Soil adsorption (Koc): No data available
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to burn in a chemical
incinerator equipped with an afterburner and scrubber system. Observe all federal, state and local regulations when
disposing of the substance.
2-Bromo-6-fluorotoluene

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
UN-No: Not Listed

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26,
2002): Safe use and production, the storage of a dangerous chemical, transport, loading and unloading were
prescribed.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

2-溴-6-氟甲苯是一种重要的医药中间体。它用于合成治疗脑神经疾病药物苯基哌啶的中间体；还用于合成治疗白介素（IL-1β）和肿瘤坏死因子-α（TNF-α）氨基二苯酮的中间体，以及具有促智作用的苯基咪唑烷酮类药物。

合成

在150毫升四口烧瓶中加入9.3克（0.05摩尔）2-溴-6-氨基甲苯和43.6克40%的HBF4溶液（0.20摩尔），于25℃反应1小时。冰盐浴降温至-5℃，然后滴加11.5克33% NaNO2溶液（0.055摩尔）。滴毕后继续在-5℃搅拌1小时。过滤后用无水乙醇洗涤两次（每次30毫升），并进行真空干燥得到13.9克氟硼酸重氮盐。

接着，在一个干燥的250毫升四口烧瓶中加入50毫升石油醚，加热至70℃。分批次投入干燥后的氟硼酸重氮盐，产生大量烟雾。用10% NaOH溶液吸收气体，直至无烟雾为止。最后通过水蒸汽蒸馏获得6.5克2-溴-6-氟甲苯，纯度为99.3%（气相色谱法），收率为68.5%。

反应信息

• 作为反应物：
  描述：

  2-溴-6-氟甲苯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 水 、 氢气 、 三甲胺盐酸盐 、 caesium carbonate 、 三乙胺 、 三苯基膦 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 、 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 27.5h， 生成 4,4’-[4-fluoro-7-(2-{4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid
  参考文献：
  名称：

  Discovery of Gemilukast (ONO-6950), a Dual CysLT₁ and CysLT₂ Antagonist As a Therapeutic Agent for Asthma

  摘要：

  An orally active dual CysLT(1) and CysLT(2) antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT(1) and human CysLT(2), respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT(1)-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT(1)- and CysLT(2)-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.

  DOI：

  10.1021/acs.jmedchem.5b00741
• 作为产物：
  描述：

  2-溴-6-氟苯甲醛腙 在 碳酸氢钠 作用下， 以100%的产率得到2-溴-6-氟甲苯
  参考文献：
  名称：

  New Practical Synthesis of Indazoles via Condensation of o-Fluorobenzaldehydes and Their O-Methyloximes with Hydrazine

  摘要：

  The reaction of o-fluorobenzaldehydes and their O-methyloximes with hydrazine has been developed as a new practical synthesis of indazoles. Utilization of the methyloxime derivatives of benzaldehydes (in the form of the major E-isomers) in this condensation effectively eliminated a competitive Wolf-Kishner reduction to fluorotoluenes, which was observed in the direct preparations of indazoles from aldehydes. Reaction of Z-isomers of methyloximes with hydrazine resulted in the formation of 3-aminoindazoles via a benzonitrile intermediate.

  DOI：

  10.1021/jo0613784

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROTHROMBOSIS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT DE L'ATHÉROTROMBOSE
  申请人：KANDULA MAHESH

  公开号：WO2013024376A1

  公开（公告）日：2013-02-21

  The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration- transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may foe used to treatment of vascular disorders or conditions such as thrombotic cerebrovascular or cardiovascular disease or its associated complications.

  本公开提供公式I的化合物或其药用可接受的盐，以及其多晶型、对映体、立体异构体、溶剂合物和水合物。这些盐可以制成药物组合物。药物组合物可以用于口服、经皮、经粘膜、糖浆、局部、延长释放、持续释放或注射的给药。这种组合物可用于治疗血管疾病或病况，如血栓性脑血管或心血管疾病或其相关并发症。
• [EN] COMPOSITIONS AND METHODS FOR TREATING ATHEROTHROMBOSIS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE LA THROMBOSE ATHÉROSCLÉREUSE
  申请人：KANDULA MAHESH

  公开号：WO2013168022A1

  公开（公告）日：2013-11-14

  Provided are compounds of formula (I), pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising the compounds may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup or injection, and may be used for the treatment or management of ischemia, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.

  提供的是式(I)的化合物，药用可接受的盐，多型体，溶剂合物，对映体，立体异构体及其水合物。包含这些化合物的药物组合物可用于口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂的配制，并可用于治疗或管理缺血、脑血栓形成、动脉血栓形成、血栓性脑血管疾病、心血管疾病和血栓。
• Prodrugs of anti-platelet agents
  申请人：Kandula Mahesh

  公开号：US09175008B1

  公开（公告）日：2015-11-03

  The invention relates to the compounds of formula I, formula II, formula Ia, formula IIb or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula Ia, formula IIb and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.

  该发明涉及公式I、公式II、公式Ia、公式IIb或其药用可接受盐，以及其多晶型、溶剂合物、对映体、立体异构体和水合物。包含公式I、公式II、公式Ia、公式IIb化合物的有效量的药物组合物，以及用于治疗或预防动脉血栓形成的方法可以制成口服、颊内、直肠、局部、经皮、经粘膜、静脉、肠道给药、糖浆或注射剂。这种组合物可用于治疗或管理缺血、中风、脑血栓形成、动脉血栓形成、血栓性脑血管疾病和血栓。
• Steroid receptor modulator compounds and methods
  申请人：Ligand Pharmaceuticals Incorporated

  公开号：US05696127A1

  公开（公告）日：1997-12-09

  Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.

  披露了对类固醇受体具有高亲和力、高选择性调节剂的非类固醇化合物。还披露了包含这些化合物的药物组合物、使用所披露的化合物和组合物治疗需要类固醇受体激动剂或拮抗剂治疗的患者的方法，以及在制备这些化合物中有用的中间体和制备类固醇受体调节剂化合物的过程。
• 8-Azabicyclo[3.2.1]octane derivatives
  申请人：Napier Elizabeth Susan

  公开号：US20070185156A1

  公开（公告）日：2007-08-09

  The present invention relates to a 8-azabicyclo[3.2.1]octane derivative of Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt thereof or solvate thereof. The present invention also relates to a pharmaceutical composition comprising an 8-azabicyclo[3.2.1]octane derivative in admixture with one or more pharmaceutically acceptable auxiliaries and to the use of the 8-azabicyclo[3.2.1]octane derivative in therapy.

  本发明涉及一种式I的8-氮杂双环[3.2.1]辛烷衍生物，其中每个取代基的定义如规范和声明中所述，或其药学上可接受的盐或溶剂。本发明还涉及一种药物组合物，其包括8-氮杂双环[3.2.1]辛烷衍生物与一种或多种药学上可接受的辅助剂混合，并且涉及在治疗中使用8-氮杂双环[3.2.1]辛烷衍生物。